Dr. Stadler on the Therapeutic Landscape of RCC

Walter M. Stadler, MD
Published: Wednesday, Apr 10, 2019



Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses the therapeutic landscape of renal cell carcinoma (RCC).

In the last 10 years or so, physicians have relied on VEGFR-targeted therapies in RCC, including pazopanib (Votrient), sunitinib (Sutent), and axitinib (Inlyta). Now, physicians are moving into an era of immunotherapy, which includes nivolumab (Opdivo), pembrolizumab (Keytruda), ipilimumab (Yervoy), and avelumab (Bavencio), enabling researchers to look at combination approaches.

Part of the rationale of exploring combinations of VEGF and immunotherapy agents is their accessibility, says Stadler. However, there is a scientific rationale for their use in combination as well. For example, some of the VEGF pathways have been shown to be immunosuppressive and may induce immunosuppressive properties, says Stadler. Some of the combinations that have been shown to be effective to date include axitinib and avelumab, axitinib and pembrolizumab, and atezolizumab and bevacizumab (Avastin).
SELECTED
LANGUAGE


Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses the therapeutic landscape of renal cell carcinoma (RCC).

In the last 10 years or so, physicians have relied on VEGFR-targeted therapies in RCC, including pazopanib (Votrient), sunitinib (Sutent), and axitinib (Inlyta). Now, physicians are moving into an era of immunotherapy, which includes nivolumab (Opdivo), pembrolizumab (Keytruda), ipilimumab (Yervoy), and avelumab (Bavencio), enabling researchers to look at combination approaches.

Part of the rationale of exploring combinations of VEGF and immunotherapy agents is their accessibility, says Stadler. However, there is a scientific rationale for their use in combination as well. For example, some of the VEGF pathways have been shown to be immunosuppressive and may induce immunosuppressive properties, says Stadler. Some of the combinations that have been shown to be effective to date include axitinib and avelumab, axitinib and pembrolizumab, and atezolizumab and bevacizumab (Avastin).



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x